Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Identifying and treating SORL1-associated Alzheimer’s disease

SORLA-FIX

The majority of the risk to develop Alzheimer's disease is influenced by genetic factors. We previously found that carrying a genetic mutation in the SORL1 gene can lead to a greatly increased chance of developing Alzheimer's Disease. SORL1 is involved in the production and processing of Alzheimer proteins that accumulate in the brain. e have...

Funding Programme
Start Date
End Date
European Countries Involved

In silico modeling of multi-domain proteins in biological condensates

MMultiDP

Neurodegenerative disorders are one of the leading causes of disabilities and death in elderly populations worldwide. To this date, no established treatment can either prevent or slow down the progression of these diseases. Their occurrences and progression are strongly correlated with insoluble biological condensates composed of nucleic acids and...

Funding Programme
Start Date
End Date
Total Funding
€ 230 774
European Countries Involved

Inflammation and AD: modulating microglia function focussing on TREM2 and CD33

PHAGO

Alzheimer’s disease (AD) is an age-related chronic neurodegenerative disease with four main pathological changes in the brain: amyloid plaques, fibrillary tau tangles, inflammation and neuronal loss. Phagocytes around amyloid plaques in late onset AD (LOAD) may be neurotoxic but have limited motility and phagocytic activity, suggesting a...

Funding Programme
Start Date
End Date
Total Funding
€ 18 088 176

Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases

IMPRiND

Assemblies of tau and α-synuclein were shown to spread along interconnected neuronal networks suggesting broadly relevant therapeutic directions for Alzheimer’s and Parkinson’s disease. This requires a pre-clinical stage of development that has yet to be met. The scale of neurodegenerative disease burden in Europe calls for an unprecedented...

Funding Programme
Start Date
End Date
Total Funding
€ 11 363 398
European Countries Involved

INNOVATIVE WATER-SOLUBLE PHYTOMATERIAL INHIBITORs FOR ALZHEIMERs AND PARKINSONs DISEASES PREVENTION

PhytoAPP

Under PhytoAPP project it is expected to build new and enhance existing network of international and inter-sectoral cooperation in the form of joint research and innovation activities between the project Partners with multidisciplinary skills and complementary competences in nanomaterials, physics, engineering, green chemistry, biochemistry and...

Funding Programme
Start Date
End Date
Total Funding
€ 1 021 200
European Countries Involved

Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain

IM2PACT

The overall aim is to further the understanding of the BBB in health and disease states towards the development of innovative brain delivery systems, especially for biopharmaceuticals (e.g., peptides, antibodies, etc.) and the identification of novel disease drug targets (Alzheimer’s Disease, MS, metabolic disease).

The related key deliverables...

Funding Programme
Start Date
End Date
Total Funding
€ 17 410 136

NAD+ International Scientist-training

NADIS

Nicotinamide adenine dinucleotide (NAD+) is a central redox cofactor and the limiting substrate of key metabolic enzymes. The constellation of cellular functions in which NAD+ is involved makes its availability critical for cell survival, and its depletion is a leading factor in a number of diseases in humans, ranging from rare inherited defects to...

Funding Programme
Start Date
End Date
Total Funding
€ 2 530 832
European Countries Involved

Nanocatalytic drugs towards Alzheimer's disease

ORGANOZYMES

Here is proposed nano-scale synthesis and combinatorial screening of medium sized peptide-transition metal catalyst libraries with the aim of producing libraries for screening highly selective catalysts for development of nano-medicines. The implementation of catalytic molecules as medicines is a new paradigm in treatment that can overcome a number...

Funding Programme
Start Date
End Date
Total Funding
€ 230 810
European Countries Involved

NANOPARTICLES FOR THERAPY AND DIAGNOSIS OF ALZHEIMER DISEASE

NAD

The search for effective therapies and early detection strategies for Alzheimer’s Disease (AD), the major cause of dementia in Europe, is imperative. It is known that β-amyloid (Aβ) peptide plays a central role in neurodegeneration. In AD brain, Aβ is released in a soluble form that progressively becomes insoluble forming aggregates; extracellular...

Funding Programme
Start Date
End Date
Total Funding
€ 14 365 090

Nanosystems for the early Diagnosis of Neurodegenerative diseases

NADINE

Medical diagnosis is currently undergoing a major revolution due to the fast discovery of molecular biomarkers, and the development of multimodal “metabiomarker” signatures. Progress, however, is hindered by low abundance of many biomarkers of interest in body fluids, in absolute concentration and with regard to other biomolecules. The aim of the...

Funding Programme
Start Date
End Date
Total Funding
€ 11 702 928
European Countries Involved

Nerve Growth Factor Delivery into the Brain – focus on therapeutic potential in Alzheimer’s disease and In Vivo Evaluation via PET

Beyond the BBB

Alzheimers disease (AD) is a neurodegenerative disease affecting the aged population and is projected to increase 3-fold in the next 30 years. Treatment options in AD are limited due to complex pathological processes and the blood-brain barrier (BBB), which restrict entry molecules into the brain. A finding in AD is the loss of cholinergic neurons...

Funding Programme
Start Date
End Date
Total Funding
€ 214 934
European Countries Involved

Novel Integrated Approach for Assembly Analysis of Intrinsically Disordered Proteins at High Resolution

IDP Assembly

Protein aggregation hallmarks several neurodegenerative diseases, including Alzheimer's and Parkinson's. In Parkinson's, aggregation of the intrinsically disordered protein (IDP) alpha-synuclein (Syn) leads to its intracellular deposition into Lewy bodies, which causes neuronal dysfunction. Recently it was discovered that Syn can undergo liquid...

Funding Programme
Start Date
End Date
Total Funding
€ 214 934
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).